Pfizer’s Drug Safety Web Site Aims To Reclaim Risk Communication Authority
BOSTON-Pfizer's new Medicine Safety Web site is the first attempt by a pharmaceutical company to reclaim authority over risk communication from FDA
You may also be interested in...
FDA is expected to miss a spate of implementation deadlines for provisions of the FDA Amendments Act as the law approaches its first anniversary
In off-label promotion investigations, OIG looks for kickback issues or other bad conduct and whether there is patient harm.
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism